HK1149497A1 - A solid pharmaceutical formulation - Google Patents

A solid pharmaceutical formulation

Info

Publication number
HK1149497A1
HK1149497A1 HK11103775.2A HK11103775A HK1149497A1 HK 1149497 A1 HK1149497 A1 HK 1149497A1 HK 11103775 A HK11103775 A HK 11103775A HK 1149497 A1 HK1149497 A1 HK 1149497A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
solid pharmaceutical
solid
formulation
pharmaceutical
Prior art date
Application number
HK11103775.2A
Other languages
English (en)
Chinese (zh)
Inventor
Tadashi Mukai
Original Assignee
Otsuka Pharma Co Ltd
Kanda Tsukasa Machi 2 Chome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40847022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1149497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd, Kanda Tsukasa Machi 2 Chome filed Critical Otsuka Pharma Co Ltd
Publication of HK1149497A1 publication Critical patent/HK1149497A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11103775.2A 2008-05-15 2011-04-14 A solid pharmaceutical formulation HK1149497A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008128259 2008-05-15
PCT/JP2009/059300 WO2009139504A2 (en) 2008-05-15 2009-05-14 A solid pharmaceutical formulation

Publications (1)

Publication Number Publication Date
HK1149497A1 true HK1149497A1 (en) 2011-10-07

Family

ID=40847022

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103775.2A HK1149497A1 (en) 2008-05-15 2011-04-14 A solid pharmaceutical formulation

Country Status (32)

Country Link
US (1) US20110091535A1 (xx)
EP (1) EP2273981B1 (xx)
JP (1) JP5552434B2 (xx)
KR (1) KR101585280B1 (xx)
CN (2) CN102119024A (xx)
AR (1) AR071706A1 (xx)
AU (1) AU2009247156B2 (xx)
BR (1) BRPI0912656A2 (xx)
CA (1) CA2722244C (xx)
CL (1) CL2009001183A1 (xx)
CO (1) CO6321223A2 (xx)
CY (1) CY1115955T1 (xx)
DK (1) DK2273981T3 (xx)
EA (1) EA022712B1 (xx)
EC (1) ECSP10010683A (xx)
ES (1) ES2524261T3 (xx)
HK (1) HK1149497A1 (xx)
HR (1) HRP20141134T1 (xx)
IL (1) IL208788A (xx)
MX (1) MX2010012432A (xx)
MY (1) MY153109A (xx)
NZ (1) NZ588794A (xx)
PE (2) PE20140962A1 (xx)
PL (1) PL2273981T3 (xx)
PT (1) PT2273981E (xx)
RS (1) RS53775B1 (xx)
SG (1) SG190643A1 (xx)
SI (1) SI2273981T1 (xx)
TW (1) TWI501789B (xx)
UA (1) UA102547C2 (xx)
WO (1) WO2009139504A2 (xx)
ZA (1) ZA201008115B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
CN103920156B (zh) * 2014-04-04 2016-06-01 成都科特包衣技术有限公司 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法
CN106511313B (zh) * 2016-10-21 2019-06-07 浙江为康制药有限公司 西洛他唑缓释胶囊组合物及其制备方法
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
JPWO2020218517A1 (xx) * 2019-04-25 2020-10-29

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US7138143B1 (en) * 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
EP1556024A4 (en) * 2002-10-25 2007-01-17 Collegium Pharmaceutical Inc INTERMITTENT LIBERATION COMPOSITIONS OF MILNACIPRANE
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
JP5112619B2 (ja) * 2004-05-20 2013-01-09 大塚製薬株式会社 固形医薬製剤
EP1945189A4 (en) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd COATED TABLETS WITH EXTENDED MAGNETIC RETENTION
WO2007105229A1 (en) * 2006-03-14 2007-09-20 Panacea Biotec Ltd. Controlled release pharmaceutical composition and process thereof
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CN101534798B (zh) * 2006-10-30 2012-02-15 韩诺生物制约株式会社 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
JP4879351B2 (ja) * 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol

Also Published As

Publication number Publication date
JP5552434B2 (ja) 2014-07-16
UA102547C2 (uk) 2013-07-25
KR101585280B1 (ko) 2016-01-13
EP2273981B1 (en) 2014-11-05
ECSP10010683A (es) 2011-01-31
AU2009247156A1 (en) 2009-11-19
IL208788A (en) 2016-05-31
AR071706A1 (es) 2010-07-07
ZA201008115B (en) 2012-01-25
PE20091900A1 (es) 2009-12-31
NZ588794A (en) 2012-07-27
DK2273981T3 (en) 2014-11-24
SI2273981T1 (sl) 2015-01-30
US20110091535A1 (en) 2011-04-21
PL2273981T3 (pl) 2015-04-30
TW201000152A (en) 2010-01-01
PE20140962A1 (es) 2014-08-15
KR20110007255A (ko) 2011-01-21
IL208788A0 (en) 2010-12-30
WO2009139504A2 (en) 2009-11-19
EA022712B1 (ru) 2016-02-29
CA2722244A1 (en) 2009-11-19
WO2009139504A3 (en) 2010-09-30
EA201071309A1 (ru) 2011-06-30
RS53775B1 (en) 2015-06-30
MY153109A (en) 2014-12-31
CN104971037A (zh) 2015-10-14
CN102119024A (zh) 2011-07-06
ES2524261T3 (es) 2014-12-04
EP2273981A2 (en) 2011-01-19
MX2010012432A (es) 2010-12-06
JP2011520774A (ja) 2011-07-21
CO6321223A2 (es) 2011-09-20
BRPI0912656A2 (pt) 2016-01-26
CL2009001183A1 (es) 2010-06-18
SG190643A1 (en) 2013-06-28
PT2273981E (pt) 2015-01-02
TWI501789B (zh) 2015-10-01
HRP20141134T1 (hr) 2015-01-30
CY1115955T1 (el) 2017-01-25
CA2722244C (en) 2016-09-13
AU2009247156B2 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
GB2450753B (en) New Pharmaceutical formulation
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
HK1169960A1 (en) Pharmaceutical formulation
IL216256A0 (en) A pharmaceutical composition
HK1149496A1 (en) A pharmaceutical composition
IL207378A0 (en) Pharmaceutical solid state forms
GB0816371D0 (en) Pharmaceutical compounds
ZA201104348B (en) Pharmaceutical preparation
GB0812969D0 (en) Pharmaceutical compounds
SI2271618T1 (sl) Farmacevtske spojine
GB0816370D0 (en) Pharmaceutical compounds
GB0815972D0 (en) Pharmaceutical preparation
HK1152640A1 (en) Pharmaceutical combination
GB0712389D0 (en) A Pharmaceutical composition
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
GB0810857D0 (en) Pharmaceutical compounds
HK1149497A1 (en) A solid pharmaceutical formulation
HU0800414D0 (en) Pharmaceutical combination
GB0805292D0 (en) Pharmaceutical formulation
GB0705030D0 (en) Pharmaceutical formulation
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230513